Gordon A Begg1,2, Rashed Karim3, Tobias Oesterlein4, Lee N Graham1, Andrew J Hogarth1, Stephen P Page1, Christopher B Pepper1, Kawal Rhode3, Gregory Y H Lip5,6, Arun V Holden7, Sven Plein2, Muzahir H Tayebjee1. 1. Department of Cardiology, Leeds General Infirmary, Leeds LS1 3EX, UK. 2. Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Clarendon Way, Leeds LS2 9JT, UK. 3. Department of Biomedical Engineering, King's College, St. Thomas' Hospital, London, SE1 7EH, UK. 4. Institute of Biomedical Engineering, Karlsruhe Institute of Technology (KIT), 76131 Karlsruhe, Germany. 5. University of Birmingham Institute of Cardiovascular Science, City Hospital, Birmingham, B18 7QH, UK. 6. Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. 7. MCRC and School of Biomedical Sciences, University of Leeds, Leeds LS2 9JT, UK.
Abstract
AIMS: Measurement of circulating biomarkers of fibrosis may have a role in selecting patients and treatment strategy for catheter ablation. Pro-collagen type III N-terminal pro-peptide (PIIINP), C-telopeptide of type I collagen (ICTP), fibroblast growth factor 23 (FGF-23), and galectin 3 (gal-3) have all been suggested as possible biomarkers for this indication, but studies assessing whether peripheral levels reflect intra-cardiac levels are scarce. METHODS AND RESULTS: We studied 93 patients undergoing ablation for paroxysmal atrial fibrillation (AF) (n = 63) or non-paroxysmal AF (n = 30). Femoral venous, left and right atrial, and coronary sinus blood were analysed using ELISA to determine biomarker levels. Levels were compared with control patients (n = 36) and baseline characteristics, including left atrial voltage mapping data. C-telopeptide of type I collagen levels were higher in AF than in non-AF patients (P = 0.007). Peripheral ICTP levels were higher than all intra-cardiac levels (P < 0.001). Peripheral gal-3 levels were higher than left atrial levels (P = 0.001). Peripheral levels of FGF-23 and PIIINP were not significantly different from intra-cardiac levels. CS levels of ICTP were higher than right and left atrial levels (P < 0.001). gal-3 was higher in women vs. men (P ≤ 0.001) and with higher body mass index (P ≤ 0.001). ICTP levels increased with reducing ejection fraction (P ≤ 0.012). CONCLUSIONS: Atrial fibrillation patients have higher levels of circulating ICTP than matched non-AF controls. In AF ablation patients, intra-cardiac sampling of FGF-23 or PIIINP gives no further information over peripheral sampling. For gal-3 and ICTP, intra-cardiac sampling may be necessary to assess their association with intra-cardiac processes. None of the biomarkers is related to fibrosis assessed by left atrial voltage. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Measurement of circulating biomarkers of fibrosis may have a role in selecting patients and treatment strategy for catheter ablation. Pro-collagen type III N-terminal pro-peptide (PIIINP), C-telopeptide of type I collagen (ICTP), fibroblast growth factor 23 (FGF-23), and galectin 3 (gal-3) have all been suggested as possible biomarkers for this indication, but studies assessing whether peripheral levels reflect intra-cardiac levels are scarce. METHODS AND RESULTS: We studied 93 patients undergoing ablation for paroxysmal atrial fibrillation (AF) (n = 63) or non-paroxysmal AF (n = 30). Femoral venous, left and right atrial, and coronary sinus blood were analysed using ELISA to determine biomarker levels. Levels were compared with control patients (n = 36) and baseline characteristics, including left atrial voltage mapping data. C-telopeptide of type I collagen levels were higher in AF than in non-AF patients (P = 0.007). Peripheral ICTP levels were higher than all intra-cardiac levels (P < 0.001). Peripheral gal-3 levels were higher than left atrial levels (P = 0.001). Peripheral levels of FGF-23 and PIIINP were not significantly different from intra-cardiac levels. CS levels of ICTP were higher than right and left atrial levels (P < 0.001). gal-3 was higher in women vs. men (P ≤ 0.001) and with higher body mass index (P ≤ 0.001). ICTP levels increased with reducing ejection fraction (P ≤ 0.012). CONCLUSIONS: Atrial fibrillation patients have higher levels of circulating ICTP than matched non-AF controls. In AF ablation patients, intra-cardiac sampling of FGF-23 or PIIINP gives no further information over peripheral sampling. For gal-3 and ICTP, intra-cardiac sampling may be necessary to assess their association with intra-cardiac processes. None of the biomarkers is related to fibrosis assessed by left atrial voltage. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Gordon A Begg; Rashed Karim; Tobias Oesterlein; Lee N Graham; Andrew J Hogarth; Stephen P Page; Christopher B Pepper; Kawal Rhode; Gregory Y H Lip; Arun V Holden; Sven Plein; Muzahir H Tayebjee Journal: PLoS One Date: 2018-01-02 Impact factor: 3.240
Authors: Mengqi Gong; Angel Cheung; Qun-Shan Wang; Guangping Li; Christos A Goudis; George Bazoukis; Gregory Y H Lip; Adrian Baranchuk; Panagiotis Korantzopoulos; Konstantinos P Letsas; Gary Tse; Tong Liu Journal: J Clin Lab Anal Date: 2020-01-09 Impact factor: 2.352
Authors: Gordon A Begg; Peter P Swoboda; Rashed Karim; Tobias Oesterlein; Kawal Rhode; Arun V Holden; John P Greenwood; Eduard Shantsila; Gregory Y H Lip; Sven Plein; Muzahir H Tayebjee Journal: J Cardiovasc Magn Reson Date: 2020-02-10 Impact factor: 5.364
Authors: Valentina A Rossi; Iva Krizanovic-Grgic; Jan Steffel; Daniel Hofer; Thomas Wolber; Corinna B Brunckhorst; Frank Ruschitzka; Firat Duru; Alexander Breitenstein; Ardan M Saguner Journal: Cardiol J Date: 2022-03-14 Impact factor: 3.487